SCHEMBL1078432

SCHEMBL1078432

Cc1ccc(C(=O)Nc2cc(C(F)(F)F)ccc2OC2CCN(C)CC2)cc1-c1cc2cnc(N)nc2c(-c2cnn(C)c2)c1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 7/20 0.59
KDR P35968 6/20 0.59
MAPK14 Q16539 6/20 0.59
JAK3 P52333 4/20 0.59
SRC P12931 2/20 0.59
TYK2 P29597 1/20 0.59
SYK P43405 1/20 0.59
BTK Q06187 1/20 0.59
WNT1 P04628 3/20 0.42
GSK3B P49841 3/20 0.42
DYRK1A Q13627 3/20 0.42
CLK2 P49760 1/20 0.42
CLK3 P49761 1/20 0.42
CSF1R P07333 4/20 0.41
BRAF P15056 2/20 0.41
TEK Q02763 1/20 0.40
DDR2 Q16832 3/20 0.40
ABL1 P00519 3/20 0.40
FGFR1 P11362 2/20 0.40
FYN P06241 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1078199 0.93 LCK (0.58) LCKKDRMAPK14JAK3SRC
SCHEMBL1078263 0.91 MAPK14 (0.60) LCKKDRMAPK14JAK3SRC
SCHEMBL1075880 0.89 KDR (0.58) LCKKDRMAPK14JAK3SRC
SCHEMBL1077802 0.87 LCK (0.49) LCKKDRMAPK14JAK3SRC
SCHEMBL1079547 0.85 KDR (0.55) LCKKDRMAPK14JAK3SRC
SCHEMBL1077490 0.84 LCK (0.60) LCKKDRMAPK14JAK3SRC
SCHEMBL1079343 0.83 LCK (0.45) LCKKDRMAPK14JAK3SRC
SCHEMBL1082055 0.82 LCK (0.60) LCKKDRMAPK14JAK3SRC
SCHEMBL1083503 0.80 LCK (0.48) LCKKDRMAPK14JAK3SRC
SCHEMBL1149466 0.79 KDR (0.60) LCKKDRMAPK14JAK3SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2269993-B1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2013-02-27 EP disclosed
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-02-17 US disclosed
EP-2269993-A1 2-AMINOQUINAZOLINE DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2011-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE H1-2, H1-3, H1-0 LCK 3187/4885KDR 896/4885MAPK14 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.